Difficult Intraoperative Heparinization Following Andexanet Alfa Administration

Direct oral anticoagulants are now commonplace, and reversal agents are recently becoming available. Andexanet alfa (AnXa), approved by the United States Food and Drug Administration in 2018, is a novel decoy molecule that reverses factor Xa inhibitors in patients with major hemorrhage. We present a...

Descripción completa

Detalles Bibliográficos
Autores principales: Watson, C. James, Zettervall, Sara L., Hall, Matthew M., Ganetsky, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University of California Irvine, Department of Emergency Medicine publishing Western Journal of Emergency Medicine 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861054/
https://www.ncbi.nlm.nih.gov/pubmed/31763596
http://dx.doi.org/10.5811/cpcem.2019.9.43650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861054/
https://www.ncbi.nlm.nih.gov/pubmed/31763596
http://dx.doi.org/10.5811/cpcem.2019.9.43650

Ejemplares similares